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Abstract
Background: Gait and balance deficits are reported in adults with HIV infection and are associated with reduced
quality of life. Current research suggests an increased fall-incidence in this population, with fall rates among middle-
aged adults with HIV approximating that in seronegative elderly populations. Gait and postural balance rely on a
complex interaction of the motor system, sensory control, and cognitive function. However, due to disease
progression and complications related to ongoing inflammation, these systems may be compromised in people
with HIV. Consequently, locomotor impairments may result that can contribute to higher-than-expected fall rates.
The aim of this review was to synthesize the evidence regarding objective gait and balance impairments in adults
with HIV, and to emphasize those which could contribute to increased fall risk.
Methods: This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines. An electronic search of published observational studies was conducted in March 2016. Methodological
quality was assessed using the NIH Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies.
Narrative synthesis of gait and balance outcomes was performed, and meta-analyses where possible.
Results: Seventeen studies were included, with fair to low methodological quality. All studies used clinical tests for
gait-assessment. Gait outcomes assessed were speed, initiation-time and cadence. No studies assessed kinetics or
kinematics. Balance was assessed using both instrumented and clinical tests. Outcomes were mainly related to
center of pressure, postural reflex latencies, and timed clinical tests. There is some agreement that adults with HIV
walk slower and have increased center of pressure excursions and -long loop postural reflex latencies, particularly
under challenging conditions.
Conclusions: Gait and balance impairments exist in people with HIV, resembling fall-associated parameters in the
elderly. Impairments are more pronounced during challenging conditions, might be associated with disease
severity, are not influenced by antiretroviral therapy, and might not be associated with peripheral neuropathy.
Results should be interpreted cautiously due to overall poor methodological quality and heterogeneity. Locomotor
impairments in adults with HIV are currently insufficiently quantified. Future research involving more
methodological uniformity is warranted to better understand such impairments and to inform clinical
decision-making, including fall-prevention strategies, in this population.
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Background
In Southern Africa, about 18.9% of adults aged 15–
49 years are HIV-1-seropositive [1]. Both globally and in
Sub-Saharan Africa, life-expectancy in people living with
HIV (PLHIV) is now comparable to that of seronegative
adults [2–4]. HIV/AIDS has evolved into a chronic con-
dition due to the success of highly-active antiretroviral
therapy (HAART) [2], but this is paralleled by increasing
morbidity. In 1990, HIV/AIDS was the 33rd most im-
portant cause of disability-adjusted life years (DALYs)
globally, but has since increased to fifth position [5]. In
Sub-Saharan Africa, a high prevalence of HIV-associated
disability, including impairments in mobility and motor
function, is reported in PLHIV [6].
Gait and balance deficits have been reported in PLHIV
despite controlled viral load [7–10] and are associated
with reduced quality of life (QOL) [11, 12]. Current
HAART regimes have less neurotoxic effects than older
versions, and thus there is a lower risk of developing
peripheral neuropathy [13]. However, the prevalence of
peripheral neuropathy remains quite high among PLHIV
(between 30% and 62%), and the prevalence of locomotor
impairments remains a concern [14–17]. PLHIV have an
increased incidence of falls [18–20], and fall rates among
middle-aged PLHIV are comparable to that of seronega-
tive older adults, aged 65 years and older [18]. These falls
are attributed to balance impairments [20].
HIV-1 infection may compromise motor function at mul-
tiple levels of the nervous system [13]. Structural MRI-
studies have shown that PLHIV present with white matter
alterations, including reduced pontocerebellar tract integ-
rity, leading to gait and postural instability [21]. It remains
unclear whether gait and balance impairments noted in
PLHIV are due to the disease process or its treatment [22].
One hypothesis is that these deficits occur as a complica-
tion of ongoing inflammation [14, 23, 24]. PLHIV, although
adherent to treatment, experience non-AIDS defining com-
plications resembling geriatric processes at an earlier than
expected age [23, 25]. Chronic immune activation may be
an underlying mechanism [23]. This accelerated aging
manifests in middle-aged PLHIV as the accumulation of
various co-morbidities, including frailty [23, 26].
Of further concern is that PLHIV are four times more at
risk of fractures due to accelerated bone demineralization
[27] and sarcopenia [28], and the proposed interplay
between these conditions [29]. Low bone mineral density
and sarcopenia are associated with balance problems and
falls [28, 30]. These complications may be intrinsic to HIV
infection (e.g. due to metabolic changes) or HAART-
induced [31]. It has been suggested that the loss in bone
mineral density is a result of increased bone turnover,
especially during the first 12 to 24 months after HAART-
initiation [32–34]. Various protease inhibitor (PI) or
nucleoside reverse transcriptase inhibitor (NRTI) type
antiretroviral therapies (ART) show a correlation with
mitochondrial toxicity [22], damaging the structure and
function of muscles. In addition, reduced central activa-
tion of muscles has also been reported in PLHIV, likely
due to impaired oxygen utilisation [35].
Information is building that PLHIV demonstrate gait and
balance impairments. However, owing to the variety of ob-
servational data, it is difficult to quantify the extent of
impairment and to gain insight into which parameters are
truly affected and clinically relevant. In elderly populations,
several gait and balance parameters have been identified as
independent predictors of fall risk, including spatiotempo-
ral, kinetic, kinematic and clinical [36–39]. To the authors’
knowledge, no previous systematic review has yet investi-
gated objective impairments of gait and balance in PLHIV.
The aim of this review is therefore to synthesize the
evidence of objective impairments of gait and balance
associated with HIV-1 infection, and to emphasize those
which could contribute to increased fall risk. We also aimed
to describe the evidence in relation to disease severity,
treatment effects, task difficulty, and peripheral neuropathy.
Methods
This systematic review was conducted according to the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines [40].
Criteria for considering studies for this review
Cohort, case-control and cross-sectional studies published
in English as peer-reviewed journal articles were considered.
Studies were included if they aimed to assess instrumented
or non-instrumented objective parameters of gait and/or
balance in adults (18–65 years of age) with HIV-1 infection,
irrespective of gender. Given the expectation that there
would be a paucity of information, studies with and without
comparison groups were considered. Quantitative gait out-
comes included, but were not limited to, kinematics, kinet-
ics, spatiotemporal measures or clinical tests. Quantitative
balance outcomes included, but were not limited to, bio-
mechanical parameters such as center of pressure (COP)
measures, and temporal measures via clinical tests. Studies
were excluded if participants’ age exceeded 65 years, as the
prevalence of locomotor impairments is known to increase
in older age even in healthy populations [41]. Studies aiming
to assess HIV-Associated Neurocognitive Disorder using a
neuropsychological test battery were also excluded, regard-
less of the use of a gross motor component, in an attempt
to focus on studies with the primary aim of objectively
assessing and describing gait or balance in PLHIV.
Search methods for identification of studies
Information sources
Six computerized bibliographic databases were searched,
namely PubMed, Science Direct, EBSCOhost (CINAHL,
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MEDLINE, Africa-Wide Information), Scopus, ProQuest
Medical Library and Google Scholar. Following a prelimin-
ary search of PubMed, a comprehensive search strategy,
including all relevant key word/terms and medical subject
headings (MeSH) was developed and adapted for use in
subsequent searching of the remaining databases. Search
terms included: (HIV-1 OR HIV Infection*) AND (motor
function OR biomechanical phenomena OR gait OR
postural balance OR locomotor function). The search was
restricted to papers published from inception of the
database to March 2016. Reference lists of all identified
documents were hand-searched to identify additional
relevant evidence. In the event of missing data, an attempt
was made to contact the authors.
Study selection
Titles and abstracts of all initial hits were screened by one
reviewer (KB). When necessary, consultation with a second
reviewer (QL) was pursued. All potential full texts were
subsequently screened by these two reviewers, and eligibil-
ity criteria were applied independently. Any discrepancies
regarding eligibility were discussed between reviewers to
reach consensus.
Data collection and analysis
Methodological quality appraisal
One reviewer (KB) appraised the methodological quality
of each included study using the National Institutes of
Health (NIH) Quality Assessment Tool for Observational
Cohort and Cross-Sectional Studies [42]. The tool is
designed to aid appraisal of internal validity (potential risk
of selection-, information-, or measurement bias, or
confounding) of cross-sectional and cohort studies and
was therefore appropriate for this review. It comprizes 14
criteria. All criteria can be answered as “yes”, “no”, “cannot
determine”, “not applicable” or “not reported”. All
responses other than “yes” indicate risk of bias. Inherent
to the design, cross-sectional studies automatically score
“not applicable” on criteria 6, 7, 10 and 13. After all 17
articles were scored by the first reviewer, two of these were
randomly selected for audit and independently scored by a
second reviewer (LM). The scores assigned by each
reviewer were compared by specifically discussing those
criteria with discrepant scores. Consistent discrepancies
were noted specifically for criteria 6, 10 and 13 for both
studies – which were resolved after agreeing that these
criteria should be scored as “not applicable” as per the
instrument’s instructions. Resultant total scores were
similar; thus it was not deemed necessary for the second
reviewer to score the remaining 15 articles as well. Each
criterion was weighted equally in the overall grading, and
studies were not excluded based on quality score, due to
the expected dearth of information.
Data extraction
Data extracted from each study were summarized using a
customized Excel spreadsheet, based on Cochrane forms.
Information about sample demographics as well as the
study aims, study design, known confounders to gait and
balance, descriptors of HIV-disease, gait or balance
analysis tool or test used, specific objective gait or balance
outcomes, dose-response evidence, treatment effects, as-
sociation of disease severity, association of peripheral
neuropathy, findings and limitations of each study were
extracted. Principle summary measures were means and
standard deviations (SD).
Data analysis or synthesis
Narrative description of data was done using text
summaries or tables as appropriate. For outcomes that
were reported in at least two studies, a meta-analysis was
conducted in Revman version 5.2, provided that homo-
geneity in the outcomes and samples existed regarding
units of measurement, test conditions, gender and disease
severity. Mean differences and 95% confidence intervals
(CI) were calculated via a random effects model, provided
that means and SD were reported, and were presented
graphically as forest plots. Symptomatic (presenting with
various symptoms of chronic HIV disease) and asymp-
tomatic (asymptomatic HIV infection/clinically latent
phase of HIV) subgroups of PLHIV were analyzed.
Results
Study selection
The initial search in March 2016 produced 799 total hits
(Fig. 1). After removing duplicates and applying eligibility
criteria, 93 potential titles remained. Thirty studies were
subsequently excluded upon reading the abstracts. The
main reasons for exclusion were that the outcome mea-
sures were not relevant to the review question, participants
were not within the specified age range, and study design
was inappropriate. Following full text review, the number
of studies for inclusion was reduced to 17. Primary reasons
for exclusion were inability to obtain full text, ineligible
participants, no raw data and outcomes that were not
relevant to the review question.
Study characteristics
Critical appraisal of study quality
Table 1 presents the methodological quality appraisal
scores of the included studies, which ranged from fair to
poor. A mean score of 40.34% was obtained, ranging from
7.14% (lowest internal validity amongst the included
studies) to 57.14% (strongest internal validity amongst the
included studies).
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Study sample description
Participant numbers varied from 19 to 447. Six studies
did not include a control group [8–10, 12, 18, 35]. Mean
ages ranged from 28 to 54.7 years. Two studies included
males only [35, 43]. Only one study [44] was conducted
in Sub-Saharan Africa. Table 2 summarizes the sample
characteristics of all participants, while HIV-specific
sample characteristics are presented in Table 3.
Study design, aims and outcomes
Sixteen studies were cross-sectional, and one was a
prospective cohort [9]. Study aims varied (Table 4), but all
included objective measurement of balance and/or gait as
part of the primary aim. Balance was assessed using both
clinical and instrumented tests. All studies used timed
clinical tests for assessing gait. No studies assessed gait kin-
etics or kinematics. Outcomes varied substantially. Table 5
(balance) and Table 6 (gait) present the outcomes assessed
per study. Summaries of the results for individual outcomes
are presented briefly in Table 7 (balance) and Table 8 (gait),
and presented in more detail as additional files (see
Additional file 1 for balance and Additional file 2 for gait).
Static balance Five studies assessed static balance using
clinical tests. One study [45] assessed Romberg eyes-
closed-on-foam and found the frequency of impairment
to be higher in PLHIV. Tandem stance time was normal
in PLHIV [21]. Four studies assessed single leg stance time
[8, 9, 21, 22]. Impairments were noted either only with
eyes closed, or with synergistic obesity, or when standing
on the non-preferred leg (eyes open and closed).
One study [46] assessed COP sway path using a force
plate, and found the incidence of increased values to be
larger in advanced stages of infection and task difficulty.
Sway velocity was examined by another study [47]. A
significant increase was found in neurologically symp-
tomatic PLHIV regardless of visual condition, and about
25% of PLHIV with asymptomatic HIV infection also
demonstrated increased values.
Average velocity in anterior-posterior (AP) and average
velocity in lateral (LAT) directions were assessed by one
study [48]. PLHIV with asymptomatic HIV infection had
significantly increased AP only in the eyes closed condi-
tion, while PLHIV with symptoms of chronic HIV dis-
ease had significantly increased AP both with eyes open
and eyes closed, as well as significantly increased LAT
(only with eyes closed).
Two studies [47, 48] assessed the coefficient of the pref-
erential direction of movement (AP/LAT ratio) and found
this to be normal in PLHIV. Romberg ratio of area (RA)
Fig. 1 PRISMA flow diagram of literature search and selection process
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as well as Way (average velocity of movement) was found
to be increased in all HIV groups [48].
Sensory Organisation Test (SOT) sway strategy score
was found to be lower (which is worse, as it indicates
more reliance on the hip strategy as opposed to the ankle
strategy) for bilateral stance (eyes closed) in PLHIV [22].
Two studies [7, 22] reported on SOT Equilibrium
Quotient (EQ) and reported significant impairments in
PLHIV during the most difficult SOT subtests (eyes closed
or inaccurate visual input).
Table 3 Sample characteristics, PLHIV
Study ID Disease staging CD4 cell count,
cells/mm3 (SD)
Viral load (SD) Treatment
Trenkwalder
1992 [46]
WR I-II (N = 17); WR III-V
(N = 19); WR VI (N = 14)
NR NR NR
Arendt
1994 [47]
CDC II (N = 12); CDC III (N = 12);
CDC IV C1 (N = 5); CDC IV C2 (N = 5);
CDC IV D (N = 2); CDC IV B (N = 10)
NR NR NR
Beckley
1998 [50]
ASX (N = 2); CDC Stage A (N = 2);
CDC Stage B (N = 2); CDC Stage
C (N = 3)
Range 65–701; 5
participants had
AIDS-defining CD4
counts (<200)
NR Most were on zidovudine maintenance
therapy
Bauer
2005 [7]
NR NRx: 351 (282);
NNRTI: 457 (375);
PI: 320 (200)
HIV burden × 1000 copies/ml:
NRx: 93.8 (163); NNRTI: 35.5
(102); PI: 20.1 (48.2)
NRx: N = 28; NNRTI: N = 25;
PI: N = 37
Simmonds
2005 [49]
Based on CD4 count
ASX (CD4 > 200) (N = 52);
AIDS (CD4 < 200) (N = 48)
Range 189.83 (183.27)
- 386.36 (302.39)
Virions:
ASX 33545.25; AIDS
193401.00
NR
Dellepiane
2005 [48]
CDC classificationASX (N = 15);
AIDS (group IV) (N = 15)
NR NR NR
Scott
2007 [35]
NR 408 (293) log copies/ml
2.18 (0.94)
All were on a NRTI-based regimen,
with 82% receiving a PI as a third agent
Richert
2011 [8]
CDC category C: 23% a520 (348, 709) <500 copies/ml: 83% 89%
Bauer
2011 [22]
NR BMI <21: 280 (52); BMI
21–29: 422 (40);
BMI > 29: 361 (64)
Log10 viral load
BMI <21: 3.06 (0.34);
BMI 21–29: 2.19
(0.26); BMI > 29: 2.08 (0.39)
% no ART/NNRTI-based ART/ PI-based ART:
BMI <21: 38.2/26.5/35.3; BMI 21–29:
31.7/26.7/
41.7; BMI > 29: 37.0/18.5/44.4
Sullivan
2011 [21]
NR M 537.4 (258.97); F
583.4 (103.55)
M 13597.6 (4654.88);
F 4609.7 (3226.36)
HAART: N = 25; Non-HAART: N = 6;
NRx: N = 9
Erlandson
2012a [10]
NR a551 (361, 768) Detectable
(≥48 copies/mL): 5%
NR
Erlandson
2012b [18]
NR 594 (16) 95% had plasma HIV-1
RNA < limits of detection
Any didanosine: Non-fallers: 57 (23);
Single fallers: 10 (23); Recurrent fallers:
24 (36) Any stavudine: Non-fallers: 93 (37);
Single fallers: 22 (51); Recurrent fallers: 33
(50) Efavirenz: Non-fallers: 86 (34); Single
fallers: 10 (23); Recurrent fallers: 22 (33)
Cohen
2012 [45]
NR 556.4 (284) Log10HIV RNA:
a3.50 (2.68, 4.42)
HAART: 76.9%
Beans
2013 [43]
NR a445 (265, 531) Non-detectable
(<400 copies/ml): 91%
Majority were receiving cART
Mbada
2013 [44]
All: Clinical stage I of HIV/AIDS
(ASX HIV infection, with PGL)
NR NR 100% HAART
Richert
2014 [9]
CDC stage C 24% a506 (340, 715) HIV RNA level < 500
copies/ml: 84%
89% on ART
Erlandson
2014 [12]
NR 594 (303) HIV-1 RNA < limits
of detection: 95%
All participants taking effective cART
Abbreviations: AIDS acquired immunodeficiency syndrome, ART antiretroviral therapy, ASX asymptomatic, BMI Body Mass Index, cART combination antiretroviral
therapy, CDC Centre for Disease Control, F female, HAART highly active antiretroviral therapy, HIV human immunodeficiency virus, IQR interquartile range, M male,
N number of participants, NA not applicable, NNRTI non-nucleoside reverse transcriptase inhibitor, NR not reported, NRTI nucleoside reverse transcriptase inhibitors,
NRx no treatment, PGL Persistent generalized lymphadenopathy, PI protease inhibitor, PLHIV people living with HI, SD standard deviation, SX symptomatic, WR
Walter Reed staging
aMedian (IQR)
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Meta-analyses (Figs. 2 and 3) were performed for postural
sway area [47, 48]. With eyes open, asymptomatic PLHIV
and controls had similar sway areas, while PLHIV with symp-
toms of chronic HIV disease demonstrated a significant
increase. Overall, sway area was significantly increased in
PLHIV (combined group of those with and without symp-
toms of HIV). With eyes closed, PLHIV with asymptomatic
HIV infection had normal sway areas, while PLHIV with
symptoms of chronic HIV disease demonstrated a significant
increase. Overall, sway area was increased in PLHIV.
Thus, the observed overall treatment effect in the com-
bined group differed across the different subgroups. Homo-
geneity seems to exist between the sample estimates within
the subgroups (I2 = 0% for all groups), while a significant
interaction existed between the subgroups (I2 = 86.4% &
87.9% for the two outcomes, respectively), suggesting that the
population parameters estimated by the subgroups are differ-
ent. It should however be noted that the conjecture about
homogeneity between sample estimates in these subgroup
does not necessarily mean that the presence/absence of
symptoms in PLHIV fully explains the heterogeneity
observed across studies. In fact, the small number of studies
and sample sizes for these outcomes might not provide
adequate statistical power in demonstrating heterogeneity.
A meta-analysis (Fig. 4) was done for Romberg ratio of
sway velocity (sway with eyes closed/sway with eyes open)
[47, 48]. PLHIV with asymptomatic HIV infection had
normal values, while PLHIV with symptoms of chronic
HIV disease demonstrated a significantly larger Romberg
ratio (which is worse as it indicates a higher amount of
visual dependency). Overall, Romberg ratios were similar
between the combined group of PLHIV and controls.
Substantial heterogeneity was found within the combined
group (I2 = 88%, p = 0.004 and I2 = 91%, p = 0.00001, re-
spectively). When splitting the subgroups according to
presence of symptoms, PLHIV with asymptomatic HIV in-
fection still showed evidence of high heterogeneity and non-
significant results regarding impairment, while symptomatic
Table 4 Study aims
Study ID Design Aim
Trenkwalder 1992 [46] Cross-sectional To measure postural performance quantitavely in PLHIV (in different disease stages)
versus seronegative controls, using a force plate.
Arendt 1994 [47] Cross-sectional To determine if stance control is impaired in early versus late HIV infection, using a
force plate, and to compare results with the COG patterns in pyramidal or extrapyramidal disease.
Beckley 1998 [50] Cross-sectional To evaluate postural reflexes with EMG in PLHIV without obvious neurological disease,
in order to determine whether postural reflexes are early markers of CNS involvement.
Bauer 2005 [7] Cross-sectional To assess sensorimotor function in PLHIV and seronegative controls.
Simmonds 2005 [49] Cross-sectional To characterize physical performance in PLHIV, and to examine group differences by pain and fatigue.
Dellepiane 2005 [48] Cross-sectional To investigate whether posturography can detect the presence of possible disorders of
the vestibulo-spinal reflex.
Scott 2007 [35] Cross-sectional To determine the extent of neuromuscular activation of selected lower limb muscles of
male PLHIV receiving ART, and its relationship to performance in clinical functional tests.
Richert 2011 [8] Cross-sectional To provide standardized assessments of locomotor function in PLHIV, focusing on lower
limb muscle performance and balance, and on potential determinants of functional impairment.
Bauer 2011 [22] Cross-sectional To compare balance and gait in participants who differ in BMI and the presence or absence of HIV/AIDS.
Sullivan 2011 [21] Cross-sectional To investigate whether infratentorial brain volume would be marked by regional tissue shrinkage
in PLHIV versus seronegative controls, and whether tissue deficits would be related to impairment
in postural stability or psychomotor speed, using structural MRI and quantitative tests of postural
stability, finger movement, psychomotor speed and dexterity.
Erlandson 2012a [10] Cross-sectional To compare the FFP, SPPB, and 400-m walk in PLHIV.
Erlandson 2012b [18] Cross-sectional To determine fall-rate and -risk factors among PLHIV by correlating fall history, medical diagnoses,
and functional tests.
Cohen 2012 [45] Cross-sectional To determine whether PLHIV on HAART had an increased prevalence of vestibular disorders
versus seronegative controls, using standard screening tests of vestibular and balance function.
Beans 2013 [43] Cross-sectional To compare locomotor function in male PLHIV versus seronegative controls, and test the association
with aerobic exercise capacity.
Mbada 2013 [44] Cross-sectional To compare HRQOL and a performance-based measure of functional capacity between a
homogenous sample of clinical stage I PLHIV versus seronegative controls.
Richert 2014 [9] Prospective cohort To prospectively assess the changes in locomotor function in PLHIV over time and to evaluate the
determinants of variations in lower limb muscle performance.
Erlandson 2014 [12] Cross-sectional To assess the impact of physical function impairments on HRQOL in PLHIV using ART.
Abbreviations: ART antiretroviral therapy, BMI body mass index, CNS central nervous system, COG centre of gravity, EMG electromyography, FFP Fried’s Frailty
Phenotype, HRQOL health-related quality of life, PLHIV people living with HIV, SPPB Short Physical Performance Battery
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Table 7 Summary of objective balance outcomes and results
Study ID Results Method of measurement Outcomes assessed
Trenkwalder
1992 [46]
b,a 4 conditions on force plate: Bilat stance EO + stable;
Bilat stance EC + stable; Bilat stance EO + foam;
Bilat stance EC + foam.
Mean sway path (m/min): EO & EC + foamb
(all PLHIV except WR I-II)/EC + stable or foamb
(all PLHIV)/All other conditions a
Arendt
1994 [47]
b,a 2 conditions on force plate: Bilateral stance EO;
Bilateral stance EC.
Sway velocity (m/s)b / AP/LAT quotient a
Beckley
1998 [50]
b,a Leg reflexes elicited in participants while standing
upright on movable force plate - surface EMG
recordings obtained from left tibialis anterior and
medial gastrocnemius
Onset latencies (SL, ML and LL) (ms) / Normalized amplitude
of MLa/LL-amplitude scaling (predictable a; unpredictable b)
Bauer
2005 [7]
b,a 1) SOT, 3 conditions: EO, EC, inaccurate visual input
2) Forward/backward lean tests
3) (Single-leg stance test)
1) SOT, for each condition: EQ. (EOa, ECb, inaccuratea)
/Number of fallsa/Time before a fall (seconds)a
2) FBOS (Lean amplitude/ft length)b
3) (Single Leg Stance time (s) - results not presented)
Simmonds
2005 [49]
a Loaded forward reach
Unloaded forward reach
Distance reached (cm)a
Richert
2011 [8]
a,c 1) BBS
2) TUG test
3) FR test
4) SLS, EC
5) 5STS
1) Berg scorea
2) TUG time (sec)a
3) Reach distance (cm)a
4) SLS time (sec)c
5) 5STS time (sec)c
Dellepiane
2005 [48]
b, a 1) Static posturography: Romberg’s position on
force plate; EO & EC
2) Dynamic posturography: EO & EC; leg reflexes
elicited via sudden tilts of moveable force plate,
EMG recorded
1) Static:
Way (EO & EC, SXb), Area, AP (ASX in ECb, SX in EOb & ECb),
LAT (SX in ECb), AP/LATa, RW, RAb
2) Dynamic (SL, ML and LL):
Latency (SL: EO & EC, all HIV groupsb) (ML: EO, SX, both legsb;
EO, ASX, left leg b; EC, all groupsa) (LL: EC, SXb; EC, ASXa)/Duration
(SL: EO, all PLHIV a; EC, SX, left legb) (ML: EO, all PLHIVa; EC, all
PLHIV, bilatb) (LL, EC, all PLHIVb) /Amplitudea/Area of single EMGa
Bauer
2011 [22]
b, a 1) SOT, 3 conditions: EO, EC, inaccurate visual input
2) Forward/backward lean tests
3) SLS test
4) 360-degree turn test
5) 5STS test
1) SOT: Dependent variables calculated for each condition were:
EQ (ECb, inaccurate inputb)
Sway strategy score (ECb)
2) LOS (lean amplitude/ft length)b
3) SLST time (seconds) (only obese PLHIV, non-preferred legb)
4) 360 deg. turn time (seconds) (only obese PLHIVb)
5) 5STS time (seconds)a
Sullivan
2011 [21]
b, a Walk-a-Line Battery. Conditions: Stand Heel-to-Toe;
Walk Heel-to-Toe; and SLS.
1) Stand Heel-to-Toe time (seconds)a
2) SLS time (seconds) (non-preferred legb)
3) Walk-Heel-to-Toe - number of steps out of 10 (ECb)
Cohen
2012 [45]
c Romberg tests on stable and on foam, 4 conditions:
EO + stable, EC + stable, EO + foam, EC + foam.
Romberg time, EC + foam (seconds)c
Erlandson
2012a [10]
c Tandem stand and 5STS as part of SPPB 5STS time (part of SPPB score)c/Tandem stance time
(part of SPPB score)c
Erlandson
2012b [18]
c Tandem stand and 5STS as part of SPPB 5STS time (part of SPPB score)c/Tandem stance time
(part of SPPB score)c
Richert
2014 [9]
c 1) 5STS test
2) TUG test
3) SLS test
1) 5STS time (seconds)c
2) TUG time (seconds)c
3) SLS time (seconds)c
Erlandson
2014 [12]
c 5STS 5STS pace (rises/s)c
Outcomes included in meta-analyses are not included in this table
Abbreviations: 5STS 5-times-sit-to-stand, AP Average velocity in anterior-posterior direction, ASX asymptomatic; BBS Berg Balance Scale, Bilat bilateral, COP center of
pressure, deg. degree, EC eyes closed, EMG electromyography, EO eyes open, EQ equilibrium quotient, FBOS functional base of support, FR functional reach, LAT
average velocity in medial-lateral direction, LL long loop, LOS limits of stability, ML medium loop, PLHIV people living with HIV, RW Romberg index reported to
way = ratio of way with EO & EC, RA Romberg index reported to area = ratio of area with EO & EC, SL short loop, SLS single leg stance, SOT sensory organization
test, SX symptomatic, TUG timed-up-and-go
ano significant difference between PLHIV and controls
bPLHIV significantly impaired compared to controls or normative reference values
cNo comparison provided/impairment quantified by reporting proportion of PLHIV with deficits
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PLHIV produced no evidence of heterogeneity (I2 = 0%)
whilst showing significant impairment for this outcome.
The high heterogeneity that exists particularly in the
asymptomatic subgroup of PLHIV might be attributed to
differences in the study populations used by the two stud-
ies. Differences existed in the sample sizes used (36
asymptomatic PLHIV in Arendt (1994) [47] versus only
15 in Dellepiane et al. (2005) [48]). Also, the age of the
asymptomatic participants in these studies differed (mean
of 36.33 versus 28 years). Finally, although both studies
had similar definitions of “symptomatic” participants, only
Arendt (1994) further classified the asymptomatic group
into CDC disease stages.
Dynamic balance Both the Berg Balance Scale [8] and
Timed-Up-And-Go (TUG) test [8, 9] were normal in
PLHIV. For 5-Times-Sit-To-Stand (5STS) time, one study
[22] found no group differences, while another [8] reported
poor performance in PLHIV. The prospective cohort [9]
reported an impaired 5STS time at baseline, and that 31%
of PLHIV had a decline in performance over 1 year that
was greater than the empirically defined threshold. Only
Table 8 Summary of objective gait outcomes and results
Study ID Results Method of assessment Spatiotemporal outcome
Bauer 2005 [7] a 8-m walk (preferred and fast) Gait speed: time (sec) to cover distancea
Cadence (time in sec for 5 steps)a
Simmonds 2005 [49] b 50-ft (15.24-m) walk (preferred and fast) Gait speed: time (sec) to cover distanceb
Scott 2007 [35] b 6MWD Distance covered (m) in 6 minb
Richert 2011 [8] c 6MWD Distance covered (m) in 6 minc
Bauer 2011 [22] b 8-m walk (preferred and fast) Preferredb and fast gait initiation time (sec)
Fastb and preferred gait speed (m/s)
Fast and preferred cadence (time in sec for 5 steps)
Erlandson 2012a [10] c 4-m walk as part of SPPB
400-m walk (fast)
Only presented as part of SPPB score
Gait speed (m/s)c
Erlandson 2012b [18] c 1) 4-m walk as part of SPPB
2) 400-m walk (fast)
1) Only presented as part of SPPB score
2) Gait speed (m/s)c
Beans 2013 [43] d,a 1) 6MWD
2) 400-m long distance corridor walk
1) Distance covered (m) in 6 mina
2) Gait speed: time (sec) to cover distanced
Richert 2014 [9] b 1) 6MWD
2) 10-m walk
1) Distance covered (m) in 6 minb
2) Gait speed (m/s)
Erlandson 2014 [12] c 400-m walk (fast pace) Gait speed (m/s)c
Outcomes included in meta-analyses are not included in this table
Abbreviations: 6MWD 6 min walk distance, m meters, min minutes, sec seconds, SPPB short physical performance battery
aNo significant difference between PLHIV and controls
bPLHIV significantly impaired compared to controls or normative reference values
cNo comparison provided/impairment quantified by reporting proportion of PLHIV with deficits
dControls performed worse
Fig. 2 Meta-analysis of sway area (μVxs) in PLHIV, eyes open
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PLHIV who were also obese performed worse in the 360-
Degree-Turn test [22]. Walk-Heel-To-Toe was significantly
impaired in PLHIV with eyes closed [21]. Two studies [8,
49] evaluated forward-reach distance, with no significant
deficits noted.
The Functional Base of Support (FBOS) or Limits
of Stability (LOS) tests were assessed by two studies
[7, 22]; both reported significant impairments in all
PLHIV.
Duration of postural reflexes was assessed by one study
[48]. With eyes closed, there was a significant reduction
for medium loop (ML) duration and long loop (LL)
duration in all HIV groups. Amplitude of postural reflexes
and area of single electromyography (EMG) potential were
normal in PLHIV [48]. Neurologically intact PLHIV
showed abnormal regulation of postural reflexes (LL amp-
litude scaling) under unpredictable, but not predictable,
perturbations [50].
Meta-analyses were conducted for postural sway latencies
[47, 48, 50] (Figs. 5, 6, 7, 8 and 9). For the left leg, short
loop (SL) latencies for combined PLHIV groups were nor-
mal, with significantly increased values only in PLHIV with
symptoms of chronic HIV disease upon further analysis.
These findings were similar for the right leg. ML latencies,
only assessed in two of the studies [48, 50] and only for the
left leg, were significantly increased in combined PLHIV
groups. In both legs, LL latencies were significantly
increased in symptomatic, but not asymptomatic, PLHIV.
The combined PLHIV group still showed a significant
increase in LL latencies.
Fig. 3 Meta-analysis of sway area (μVxs) in PLHIV, eyes closed
Fig. 4 Meta-analysis of Romberg ratio of sway velocity in PLHIV
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Gait Gait speed was assessed in eight studies [7, 9, 10, 12,
18, 22, 43, 49]. PLHIV demonstrated slowing of fast gait
speeds [18, 43, 49]. One study [7] found no significant dif-
ferences between PLHIV and controls, regardless of pace.
Meta-analysis [44, 49] (Fig. 10) indicated that 6-Minute
Walk Distance (6MWD) was significantly shorter (worse)
in PLHIV compared to controls. The likelihood of high
heterogeneity in this meta-analysis should be considered
(I2 = 65%, p = 0.09) and might be due to the use of histor-
ical controls in one study [49] and differences in disease
staging between the two studies. Among the un-pooled
studies, three reported a decreased (worse) 6MWD [8, 9,
35], and one study found no impairment in PLHIV [43].
One study reported no impairments in PLHIV in cadence
[7] and another reported that only PLHIV who were also
obese were significantly impaired [22]. This study also
reported that PLHIV had significantly delayed (worse)
normal gait initiation time.
Falls One study [50] reported that fall incidence during
unpredictable perturbations was similar in PLHIV versus
controls. Similarly, another study [7] found no group dif-
ferences in falls during SOT conditions. In contrast, one
study reported a similar fall rate in middle-aged PLHIV
(mean 52.0 years) and seronegative older adults (≥65 years)
[18]. Impaired balance was a major associated factor. In
addition, recurrent fallers had significantly slowed gait
versus non-fallers. Furthermore, in a prospective cohort
[9], it was reported that 12% of PLHIV experienced a
minimum of one fall in the previous year. In PLHIV with
recurrent falls, baseline 5STS time and 6MWD were
significantly impaired, compared to non-fallers.
Measurement conditions and task difficulty Twelve
studies included some form of increasing task difficulty,
such as different visual input, stable versus unstable
support surfaces, decreased base of support, predictable
and unpredictable external perturbations, and walking at
preferred versus fast gait speeds. Of these, nine (75%)
demonstrated that both balance and gait impairments were
more evident in more difficult task conditions, when com-
paring PLHIV to controls [7, 10, 18, 21, 22, 45, 46, 49, 50].
Disease severity Fifteen studies reported on the relation-
ship between HIV-disease severity and locomotor per-
formance. Of these, eight (53%) indicated a relationship
between HIV-disease severity and impairments [7, 8, 10,
35, 46–48, 50]. In contrast, seven studies (46%) found no
significant differences based on CD4 counts or viral loads
[9, 21, 22, 43, 45, 49, 50].
Fig. 5 Meta-analysis of left leg postural reflex latencies in PLHIV: short loop latencies (ms)
Fig. 6 Meta-analysis of left leg postural reflex latencies in PLHIV: medium loop latencies (ms)
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Treatment effects Seven studies reported on the relation-
ship between ART and impairments in gait and/or balance,
and none of these found any association [7–10, 21, 22, 35].
Peripheral neuropathy Five studies reported on the as-
sociation between peripheral neuropathy and impairments
in gait and/or balance in PLHIV, and none of these found
statistically significant correlations between peripheral
neuropathy and impairments of gait, dynamic balance or
static balance [7, 8, 21, 46, 47].
Discussion
The aim of this review was to establish the current state
of knowledge regarding objective impairments of gait and
balance in PLHIV, and to emphasize those which could
contribute to increased fall risk. To the authors’ know-
ledge, this is the first work to do so. Our findings indicate
that certain aspects of gait and balance are impaired in
middle-aged PLHIV, resembling those proven to predict
increased fall risk in elderly populations.
The methodological quality of articles ranged from fair
to low, partly as a direct consequence of observational
design. Earlier studies in particular had a high risk of se-
lection bias due to omitting important information such
as participant demographics and exclusion criteria. The
psychometric properties of the different tests used to as-
sess outcomes have not yet been evaluated in PLHIV;
therefore, they cannot be assumed to be valid and reliable
in this specific population. Balance and gait in PLHIV may
be influenced by various factors apart from HIV-status.
Fig. 7 Meta-analysis of left leg postural reflex latencies in PLHIV: long loop latencies (ms)
Fig. 8 Meta-analysis of right leg postural reflex latencies in PLHIV: short loop latencies (ms)
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Although studies on average controlled and adjusted for
many key confounders such as age, gender, BMI, markers
of HIV and co-morbidities, very few reported on covari-
ates such as level of education or adherence to treatment,
and none on level of physical activity.
Various gait and balance parameters, including slowed
gait speed [38], cadence [51], slowed gait initiation time
[52] slowing of postural reflexes [53], and increased
COP displacement and velocity [54] have been estab-
lished to be associated with increased risk of falls in the
elderly. Similarly, some of these variables are associated
with risk of falls in PLHIV, namely slowed gait speed
and impaired dynamic balance [18]. It has been reported
that the best fall risk predictors in PLHIV are those
proven to be predictors of fall risk in the elderly [18].
Static balance
Static balance is often quantified in terms of COP move-
ment [55], which reflects neuromuscular control to keep
the center of mass (COM) within the base of support’s
limits of stability [56–58]. Increased COP movement and
velocity is associated with increased fall risk in the elderly
[54]. In this review, evidence of increased postural sway or
velocity was found in all studies evaluating these parame-
ters, especially under challenging conditions [46–48], and
was confirmed by meta-analyses. Impaired COP sway in
PLHIV with asymptomatic HIV infection may suggest early
involvement of postural control due to direct infection of
the CNS by HIV. However, in neurologically symptomatic
PLHIV, it cannot be assumed that anatomical structures or
direct HIV-involvement of the CNS causes the observed
deficits [46]. Lower limb muscle impairment might impair
a person’s ability to correct a shift in the body’s COP to
effectively prevent a fall [59]. In the elderly, it has been
proposed that increased COP movement may be inter-
preted as an increase in hip abductor muscle activity to
control postural stability on the medial-lateral direction
[59]. It has also been suggested that decreased postural
control with larger body sway increases tibialis anterior/so-
leus muscle co-activation, inducing the hip-strategy to pre-
serve balance [60]. Greater co-activation may be partly be a
compensation for decreased lower limb muscle strength
and power [61]. As lower limb muscle impairments occur
in PLHIV, this might contribute to the impaired COP
parameters observed. HIV-associated vestibular dysfunction
has also been reported [62]. Vestibular disorders have a
deleterious effect on postural stability [63]. However,
vestibular conditions are not characterised by impaired
COP excursion, but rather by an increased frequency of
movement, indicating poor control of COP [63].
A lower sway strategy score (the relative amount of
high-frequency ankle versus low-frequency hip move-
ment) for bilateral stance with eyes closed was found in
PLHIV, albeit only reported in a single study in this review
Fig. 9 Meta-analysis of right leg postural reflex latencies in PLHIV: long loop latencies (ms)
Fig. 10 Meta-analysis of 6-Minute Walk Distance (m) in PLHIV
Berner et al. BMC Musculoskeletal Disorders  (2017) 18:325 Page 20 of 26
[22], indicating a heavier reliance on the hip-strategy. In
the general population, intact individuals will change their
balance strategy from the normally employed ankle strat-
egy, to relying on the hip strategy [56] when faced with
more challenging conditions. Individuals with impaired
balance, who already rely more heavily on the hip strategy,
are less able to adapt to challenging conditions [56].
The SOT Equilibrium Quotient (EQ) is a calculation
of the average COP sway, with lower EQ scores having
been associated with increased fall risk in the elderly
[64]. The two studies evaluating this outcome [7, 22] re-
ported significantly lower EQ scores in PLHIV, especially
with more challenging conditions.
Reduced single leg stance time is predictive of some
(i.e. injurious), but not all, falls in the elderly [65]; how-
ever, the clinical value of this test might be called into
question. The test might suffer from learning effects
[66], leading to possible ceiling effects even in individ-
uals with substantial impairment when only performed
as a clinical test. Due to differences in the reporting of
results among the included studies assessing this out-
come, it is difficult to draw conclusions regarding im-
pairment and the value of the test in PLHIV.
Dynamic balance
Dynamic balance is often assessed using dynamic posturo-
graphy, which involves external perturbations being induced
while a person tries to maintain an upright posture [56]. A
common postural synergy in this scenario is the distal-to-
proximal ankle strategy, involving a short loop (SL) and
medium loop (ML) response in the gastrocnemius, followed
by a long loop (LL) response in the tibialis anterior [67, 68].
Prolonged stance-stabilizing LL responses have been docu-
mented in elderly fallers [69]. Meta-analyses indicated that
LL latencies were increased in symptomatic but not asymp-
tomatic PLHIV, and upon combining all groups of PLHIV,
LL latencies were still significantly increased. It is suggested
that the early-observed prolonged LL latencies in PLHIV
with asymptomatic HIV infection may indicate alterations
in the central dopaminergic system (basal ganglia, caudatus
nucleus and nigrostriatal system) [48].
Scaling of LL latency-amplitude, referring to the ability to
adjust the size of posturally stabilizing reflexes and another
important factor associated with falls [53], was assessed in
one study [50]. Neurologically intact PLHIV showed ab-
normal postural reflex regulation under unpredictable,
but not predictable, perturbations. Under random con-
ditions, PLHIV automatically selected a LL response of
a relatively similar size to one needed for medium
perturbations. This response may not be sufficient to
correct for large perturbations, leading to an increased
risk of falling. However, the authors noted that the
impairment in PLHIV was “mild” and did not appear
clinically significant in early HIV infection.
The Limits of Stability (LOS) or Functional Base of Sup-
port (FBOS) test involves instrumented measurement of a
forward leaning task and evaluates voluntary control of
the center of gravity (COG). Instrumented LOS or FBOS,
unlike the clinical Functional Reach test [8, 49], was im-
paired in PLHIV [7, 22]. Similarly, the Functional Reach
test has been proven not to be an indicator for differenti-
ating elderly fallers from non-fallers [70], while instru-
mented LOS is an early indicator of increased fall risk in
the elderly [71]. These observations may be attributable to
the differences in the task involved in the clinical versus
the instrumented tests (although both assesses LOS) [71].
The 5STS test is an indicator of dynamic balance. Im-
paired performance was noted in two of the three studies
evaluating this outcome [8, 9]. In addition to impaired
central sensorimotor components being proposed to play
a role [9], impaired 5STS time also implies poor lower
limb muscle performance, which is associated with falls
and disability both in HIV-seronegative elderly popula-
tions and in middle-aged PLHIV [8, 18]. Low appendicular
muscle mass is prevalent in PLHIV and associated with
functional impairment [72]. However, a decline in the abil-
ity of muscles to produce strength and power (dynapenia)
might have a bigger contribution to functional decline in
the elderly and is associated with poor chair-rise-time [73]
Intra-muscular impairments, including fatty muscle infil-
tration, and low central activation are reported in PLHIV
[29, 35, 74] and premature expression of genes associated
with muscle aging is upregulated in PLHIV [75]. Grip
strength might correlate with dynapenia in the elderly
[76], and an accelerated decline in grip strength has been
reported in PLHIV [77].
Owing to the dichotomous assessment by clinical tests
of the ability to maintain standing balance, such tests
only detect impaired balance once compensation strat-
egies fail [56]. Selection of effective compensation strat-
egies to restore balance (especially by persons who are
physically active), might hide impairments, potentially
hampering the use of such tests in active individuals or
at an early stage of disease [56]. Level of physical activity
was not assessed by any studies included in this review;
ceiling effects in the results provided by the clinical
balance tests can therefore not be excluded.
Although more suited to quantification of balance, inter-
pretation of the results of instrumented posturography is
complex. Generally, an increase in COP movement is as-
sumed to reflect impaired balance; but this may not be true
[78, 79]. Due to the interdependent relationship of the
underlying systems, selection of an alternative compensation
strategy to maintain stance could lead to observation of ei-
ther increased or decreased COP movement, which in fact
would reflect optimal balance control [56]. Second, altered
COP movement can result from deterioration of several
underlying systems. Thirdly, COP movement is affected by
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training and learning effects, for example, individuals (and
even more so those trained in sports) might be able to
maintain a position very well, despite severe system deterior-
ation, due to becoming familiar with the task or using select-
ing proper strategies for efficient compensation [56].
Results, especially from singular studies, must thus be con-
sidered cautiously and in the context of the assessment
protocol, e.g. number of trials, and participant characteris-
tics, such as activity level.
Gait
In this review, PLHIV exhibited impaired fast, but not pre-
ferred, gait speeds, despite being on successful HAART [10,
12, 22, 49]. PLHIV who were also recurrent fallers, had an
even slower fast-paced gait [18]. Gait speed is reported as a
predictor of falls in geriatric populations, with a linear rela-
tionship between slow gait speed and increased fall risk
often assumed [80–82]. However, a non-linear relation has
also been proposed [38]. Growing evidence show that gait
and cognition, specifically attention and executive function
[83] are interrelated. Neurocognitive decline occur in HIV
[6, 13, 84–86], is in part associated with reduced dopamin-
ergic function [87], and has been associated with slow gait
speeds in this population [88]. Executive function, motor
skills and attention/working memory are some of the
domains that are affected by HIV [89]. Gait slowing is sug-
gested to be an adaptive mechanism to prevent falls, to the
effect that a slow gait speed might actually be associated
with a reduced fall risk [38].
Six-Minute Walk Distance, which is actually an indica-
tor of functional aerobic capacity, has been shown to cor-
relate well with gait speed [90]. Meta-analyses of two
studies [44, 49] suggests decreased 6MWD, and thus de-
creased gait speed under fast conditions, in PLHIV. Six-
Minute Walk Distance was also reported to be decreased
in PLHIV in the majority of un-pooled studies assessing
this outcome [8, 9, 35] – however all of these studies used
predicted values from the literature. This is of concern, as
community-specific or cultural factors influence gait
speed [43]. Gait initiation time was reported to be signifi-
cantly slowed in PLHIV, albeit data from a single study
[22]. Gait initiation time has been associated with in-
creased fall risk in the elderly [52]. Cadence, which also
has an association with gait speed and falls in the elderly
[91], was assessed by two studies [7, 22], but owing to
contradicting results, no firm conclusions can be drawn.
Measurement conditions and task difficulty
Evaluating performance under conditions of varying diffi-
culty can provide more “real-life” insight into the quality
of the specific underlying sensory systems [56, 92]. Studies
assessing balance included in this review employed differ-
ent sensory conditions, eliminating or disturbing the in-
formation of three main sensory systems. These included
variations in visual input, different base-of support sizes
and variations in support surfaces. For dynamic balance
assessments, perturbations of varying amplitudes and pre-
dictability were induced using platform tilts. There was an
overall tendency of PLHIV to perform similar to controls
in easier conditions, and significantly worse with increased
task difficulty. A correlation between static balance deficit
and eyes closed conditions was demonstrated by clinical
as well as instrumented tests [7, 22, 48]. Unstable condi-
tions with eyes closed showed the greatest abnormalities
in postural balance [45, 46]. Sullivan et al. (2011) [21]
found impaired performance among PLHIV during clin-
ical tests involving reduced base of support. Postural reflex
synergies also appear to be task-dependent. Unpredictable
perturbations resulted in worse dynamic balance perform-
ance [50]. It thus seems that PLHIV may have impaired
response to unexpected perturbations or more complex
tasks, predisposing them to falls. In the case of impair-
ment of any of the systems contributing to postural
balance, alternative compensation strategies are used by
an individual to maintain postural control and orientation
[56, 93]. Sensory reweighting comes into play, i.e. the
nervous system will rely on more accurate sensory input,
rather than less accurate, conflicting information [94].
Individuals relying more on one particular balance system
are thus less able to adapt to situations where input to that
system is disturbed, and have to rely on only the
remaining systems [56]. This sensory reweighting seems
impaired in PLHIV. Also, impaired dual-task performance
has been demonstrated in PLHIV [95], although none of
the included studies assessed this condition.
All gait tests in included studies were conducted on level,
unobstructed walkways. During walking, many falls occur
not during normal walking, but rather when negotiation
challenging terrains. Results might have been more clinic-
ally relevant had irregular or unfamiliar surfaces been
assessed, especially since dynamic balance in PLHIV seem
to be more impaired under challenging circumstances.
However, both self-selected and fast gait speed conditions
were evaluated, with group differences mostly found when
comparing fast gait. It has been suggested that walking at
different speeds likely influences both the noise level in
human motor performance as well as dynamic error cor-
rections [96]. Thus, impairments at fast paced conditions
may indicate deficits under more challenging conditions.
Disease severity
A dose–response relationship between HIV disease severity
and locomotor impairment was suggested in 53% of stud-
ies. In addition, subgroup analyses highlighted impairments
in postural reflex latencies that were inconspicuous in a
combined group of all PLHIV, but became apparent in only
those with symptoms of chronic HIV disease when com-
pared to controls. However, methodologically it remains a
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challenge to attribute observed differences between PLHIV
and controls directly to HIV infection, as evident from the
discussion thus far. Comparison populations most likely
always differ in terms of many confounding factors [8]. It
cannot be assumed with certainty that observed impair-
ments are purely related to severity of HIV infection, and
the contribution of various comorbidities and opportunistic
infections should be considered. This is especially true for
the older studies, where eligibility criteria did not control
for various confounders and comorbidities.
Treatment effects: Antiretroviral therapy (ART),
combination antiretroviral therapy (cART) or highly active
antiretroviral therapy (HAART)
The majority of studies reporting on treatment effect
failed to find significant associations to balance or gait
outcomes in PLHIV, regardless of the different combina-
tions of drugs (terms used for combination use of ARV
including ART, cART or HAART). Thus, antiretroviral
therapy does not appear to be a reversing factor with re-
gard to locomotor impairments.
Peripheral neuropathy
None of the five studies reporting on the association be-
tween peripheral neuropathy and locomotor impairments
found any significant relationships. A possible explanation
for balance abnormalities among PLHIV, at least for those
parameters measured by the included studies, might thus
indicate involvement of the central rather than peripheral
nervous system [7, 8, 21, 46, 47]. The fact that eyes closed
conditions were often necessary to elicit group differences
in balance, further motivates CNS dysfunction as an
underlying mechanism [7]. It is reported that deficits in
infratentorial brain tissue volume and disruption of the
pontocerebellar fiber system microstructure, at least in
part, may contribute to locomotor impairments in PLHIV
[21]. It can, however, not be concluded with certainty that
no association exists between gait or balance and periph-
eral neuropathy in PLHIV. It is possible that peripheral
neuropathy adversely affects gait and balance parameters
that were not measured in these studies. For example,
impairments in joint kinematics (assessed by none of the
included studies in this review) have been associated with
peripheral neuropathy in Type 2 diabetic patients [97].
Implications for future research
While the importance of identifying spatiotemporal defi-
cits is acknowledged, the associated kinematic and kinetic
data can provide more insight into underlying mecha-
nisms of the observed impairments. Some locomotor im-
pairments related to early functional decline might be too
small to be detected by visual observation alone in the
clinical setting [51, 98]. These subtle impairments may
however have substantial consequences for the individual.
Thus, there is a need for more robust quantitative assess-
ment, such as three-dimensional biomechanical motion
analysis. We also suggest the use of dual tasking in PLHIV
to assess the subtler changes in function, and adding more
challenging conditions to gait assessments. Furthermore, a
need exists for higher quality research. Carefully selected,
representative samples will make results more homoge-
neous, relevant and generalizable. In addition, valuable in-
formation can be extracted from the geriatric literature
that is likely to inform research in PLHIV, especially with
regards to data on falls and specific movement impair-
ments. This should be further explored, and the psycho-
metric properties of both instrumented and clinical gait
and balance assessments should be determined specifically
in PLHIV. Lastly, we found the lack of studies conducted
in Sub-Saharan Africa, the epicenter of the HIV epidemic,
surprizing. More research is needed in developing coun-
tries to address this gap.
Review limitations
Language bias is likely in this review, as only studies pub-
lished in English were considered. Another limitation of
the review is that only two included articles were appraised
by more than one reviewer, meaning that fifteen of the
seventeen articles were scored for methodological quality
by only one reviewer. In addition, ceiling effects might have
hampered results from clinical tests. No studies in this re-
view measured COM movement, with a subsequent in-
complete representation of balance in PLHIV at present.
Results of this review should be interpreted with caution as
substantial statistical heterogeneity existed between the in-
cluded studies, albeit expected, as evident in the meta-
analyses (indicated by high I2 values). Due to the small
number of studies per outcome, all sources of heterogen-
eity could not be accounted for, but some possible explana-
tions for variation in results have been discussed. Clinical
heterogeneity was evident in the majority of studies, par-
ticularly in terms of setting, sample sizes, age groups, gen-
der distributions, and HIV-staging. A wide variety of study
outcomes and measurement methods were used. Given
the paucity of research on existing impairments and the
optimal method of evaluating these in PLHIV, the wide
variation in assessment tests used was to be expected.
Although the diversity in populations, especially regarding
disease definition and subgroups, might seem surprising, it
must be kept in mind that HIV classification systems have
evolved substantially since the earliest included study and
that HAART regimes did not yet exist in those earlier
periods. Furthermore, publication- and reporting biases are
suspected in this review, due to many authors collaborating
on different papers and the same populations possibly used
in different studies. However, formal assessment using
funnel plots was not possible due to the low number (<10)
studies assessing a similar outcome.
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Conclusions
This review found that young to middle-aged PLHIV have
impairments in certain aspects of gait and balance, which
are similar to those that predispose elderly seronegative
populations to falls. The impairments are more pro-
nounced during challenging conditions, might be associ-
ated with HIV disease severity, are not influenced by ART,
and might not necessarily be associated with peripheral
neuropathy. Results should be interpreted with caution
due to the overall fair to low methodological quality, sub-
stantial heterogeneity and many outcomes being assessed
by singular studies only. The effect of HIV on gait and
balance parameters, and in particular biomechanical
outcomes, are currently insufficiently quantified and
this review provides a first step to inform future re-
search. Further investigation involving more methodo-
logical uniformity is warranted to better identify and
understand relevant locomotor impairments in PLHIV.
Only then can more clinically relevant conclusions,
such as appropriate strategies for fall-prevention in this
population, be drawn.
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